Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17270581 | 0.90 | SCN9A (0.37) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL17270536 | 0.88 | SCN9A (0.41) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL17270569 | 0.87 | SCN9A (0.34) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL15645542 | 0.86 | SCN9A (0.41) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL17270538 | 0.86 | SCN9A (0.47) | SCN9ACYP2C9SCN5A | |
| SCHEMBL17270530 | 0.84 | SCN9A (0.36) | SCN9A | |
| SCHEMBL17270578 | 0.83 | SCN9A (0.36) | SCN9A | |
| SCHEMBL17270550 | 0.81 | SCN9A (0.40) | SCN9ACYP2C9SCN5ASCN8A | |
| SCHEMBL17270531 | 0.80 | SCN9A (0.37) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| SCHEMBL17270520 | 0.79 | SCN9A (0.38) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376429-B2 | Sodium channel blockers, preparation method thereof and use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20150336944-A1 | Sodium Channel Blockers, Preparation Method Thereof and Use Thereof | IN THERAPEUTICS (KR) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336944-A1 | Sodium Channel Blockers, Preparation Method Thereof and Use Thereof | SCN7A, SCN1A, SCN5A | SCN9A 8/4885CYP2C9 1306/4885SCN5A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.